220 related articles for article (PubMed ID: 36646322)
1. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
6. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Serrao S; Solaimani P; Budde LE; Mei MG; Popplewell LL; Siddiqi T; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Nov; 140(19):2024-2036. PubMed ID: 35914220
[TBL] [Abstract][Full Text] [Related]
8. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR; Oluwole OO; Kersten MJ; Miklos DB; Perales MA; Ghobadi A; Rapoport AP; Sureda A; Jacobson CA; Farooq U; van Meerten T; Ulrickson M; Elsawy M; Leslie LA; Chaganti S; Dickinson M; Dorritie K; Reagan PM; McGuirk J; Song KW; Riedell PA; Minnema MC; Yang Y; Vardhanabhuti S; Filosto S; Cheng P; Shahani SA; Schupp M; To C; Locke FL; ;
N Engl J Med; 2023 Jul; 389(2):148-157. PubMed ID: 37272527
[TBL] [Abstract][Full Text] [Related]
9. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Nastoupil LJ; Jain MD; Feng L; Spiegel JY; Ghobadi A; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Vu K; Andreadis C; Munoz J; Westin J; Chavez JC; Cashen A; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Locke FL
J Clin Oncol; 2020 Sep; 38(27):3119-3128. PubMed ID: 32401634
[TBL] [Abstract][Full Text] [Related]
10. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Perales MA; Kuruvilla J; Snider JT; Vadgama S; Blissett R; El-Moustaid F; Smith NJ; Patel AR; Johnston PB
Transplant Cell Ther; 2022 Nov; 28(11):750.e1-750.e6. PubMed ID: 35970302
[TBL] [Abstract][Full Text] [Related]
11. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
12. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R; Bachy E; Cartron G; Gros FX; Morschhauser F; Oberic L; Gastinne T; Feugier P; Duléry R; Thieblemont C; Joris M; Jardin F; Choquet S; Casasnovas O; Brisou G; Cheminant M; Bay JO; Gutierrez FL; Menard C; Tarte K; Delfau MH; Portugues C; Itti E; Palard-Novello X; Blanc-Durand P; Al Tabaa Y; Bailly C; Laurent C; Lemonnier F
Nat Med; 2023 Oct; 29(10):2593-2601. PubMed ID: 37710005
[TBL] [Abstract][Full Text] [Related]
13. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
15. The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.
Hillis C; Vicente C; Ball G
Pharmacoeconomics; 2022 Sep; 40(9):917-928. PubMed ID: 35844002
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
17. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
[TBL] [Abstract][Full Text] [Related]
18. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
Transplant Cell Ther; 2024 Jan; ():. PubMed ID: 38281590
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States.
Li N; Lei J; Zhang J; Cai H; Zheng B; Yang T; Liu M; Hu J
Ther Adv Hematol; 2023; 14():20406207231168215. PubMed ID: 37250912
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
